Printer Friendly

United Kingdom : Is Open Innovation becoming the new normal in medicines research?

Open Innovation our pioneering initiative for sharing our compounds, technology and expertise with academic and industry collaborators could soon become the new normal for medicines research.

Hundreds of leading scientists from all over the world have become enthusiastic partners in the programme since its launch in March 2014. We have received over 400 Open Innovation proposals from researchers in 28 countries across four continents. They provide compelling evidence of the value of our partnering opportunities to aid development of breakthrough medicines for patients in greatest need.

I hope that our pioneering approach to Open Innovation will spread across the industry and academia and become the new normal, says Craig Wegner, Executive Director, Emerging Innovations, Scientific Partnering & Alliances, IMED Biotech Unit. It is enabling us to advance projects that neither we nor our partners would be able to do alone and create new therapies for patients.

In just 2 years, we have formed 150 Open Innovation partnerships. Nine out of 10 are with academic scientists, the rest with science-focused companies. Institutional partners include the National Institutes of Health (NIH) and the National Center for Advancing Translational Research (NIH-NCATS) in the US, the Medical Research Council (MRC) in the UK and the National Research Program for Biopharmaceuticals (NRPB) in Taiwan.

[c] 2016 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Nov 9, 2016
Words:221
Previous Article:Philippines : Cotabato backs DILGs MASA MASID program.
Next Article:United States : United States Establishes WTO Panel to Review Dispute Challenging Chinas Export Restraints on Key Raw Materials.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters